SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review
DOI:
https://doi.org/10.12775/JEHS.2024.75.56369Keywords
SGLT2 inhibitors, type 2 diabetes mellitus, chronic kidney disease, diabetic kidney diseaseAbstract
Introduction
Type 2 diabetes mellitus (T2DM) is an increasing health concern, and diabetic kidney disease (DKD) affects 30–40% of patients with diabetes. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are effective medications used in the treatment of T2DM, which not only improve glycemic control but also slow the progression of diabetic kidney disease (DKD), reducing the risk of renal and cardiovascular complications. They work by decreasing glomerular hyperfiltration and alleviating inflammation in the kidneys. Clinical studies have demonstrated significant therapeutic benefits, including a reduction in albuminuria and improvement in renal function. In the future, the development of new drug classes, such as Nrf2 activators and RAS inhibitors, which are currently under clinical investigation, may further advance the treatment of DKD, offering a more personalized approach to therapy. This article reviews the current knowledge on SGLT2i and their impact on the progression of DKD, the future prospects for therapies in managing diabetes and its complications.
Aim of the Study: The aim of this study was to gather and analyze available scientific publications regarding the effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on slowing the progression of chronic kidney disease (CKD) in patients with T2DM and to determine the future of therapy based on new reports and research into emerging drug classes.
Materials and Methods: We conducted a review and analysis of the literature available in the PubMed database, using keywords such as SGLT2 inhibitors, gliflozins, chronic kidney disease, type 2 diabetes.
References
Reed J, Bain S, Kanamarlapudi V. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes Metab Syndr Obes. 2021 Aug 10;14:3567-3602. doi: 10.2147/DMSO.S319895. PMID: 34413662; PMCID: PMC8369920.
Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, Yin X, Xu Q. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023 Apr 21;14:1161521. doi: 10.3389/fendo.2023.1161521. PMID: 37152942; PMCID: PMC10161731.
Rizzo MR, Di Meo I, Polito R, Auriemma MC, Gambardella A, di Mauro G, Capuano A, Paolisso G. Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment. Pharmacol Res. 2022 Feb;176:106062. doi: 10.1016/j.phrs.2022.106062. Epub 2022 Jan 10. PMID: 35017046.
DeFronzo RA, Bakris GL. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. Diabetes Obes Metab. 2022 Jul;24(7):1197-1205. doi: 10.1111/dom.14696. Epub 2022 Apr 18. PMID: 35302284; PMCID: PMC9323420.
Bonner R, Albajrami O, Hudspeth J, Upadhyay A. Diabetic Kidney Disease. Prim Care. 2020 Dec;47(4):645-659. doi: 10.1016/j.pop.2020.08.004. Epub 2020 Sep 23. PMID: 33121634.
Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes. 2003 Apr;52(4):1036-40. doi: 10.2337/diabetes.52.4.1036. PMID: 12663477.
Tuttle KR, Agarwal R, Alpers CE, Bakris GL, Brosius FC, Kolkhof P, Uribarri J. Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney Int. 2022 Aug;102(2):248-260. doi: 10.1016/j.kint.2022.05.012. Epub 2022 Jun 3. PMID: 35661785.
Rhee CM, Kalantar-Zadeh K, Tuttle KR. Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease. Curr Opin Nephrol Hypertens. 2022 Jan 1;31(1):72-81. doi: 10.1097/MNH.0000000000000756. PMID: 34750332; PMCID: PMC8684381.
Mohandes S, Doke T, Hu H, Mukhi D, Dhillon P, Susztak K. Molecular pathways that drive diabetic kidney disease. J Clin Invest. 2023 Feb 15;133(4):e165654. doi: 10.1172/JCI165654. PMID: 36787250; PMCID: PMC9927939.
Rabelink TJ, de Zeeuw D. The glycocalyx--linking albuminuria with renal and cardiovascular disease. Nat Rev Nephrol. 2015 Nov;11(11):667-76. doi: 10.1038/nrneph.2015.162. Epub 2015 Oct 13. PMID: 26460356.
Ramnath RD, Butler MJ, Newman G, Desideri S, Russell A, Lay AC, Neal CR, Qiu Y, Fawaz S, Onions KL, Gamez M, Crompton M, Michie C, Finch N, Coward RJ, Welsh GI, Foster RR, Satchell SC. Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease. Kidney Int. 2020 May;97(5):951-965. doi: 10.1016/j.kint.2019.09.035. Epub 2019 Nov 2. PMID: 32037077; PMCID: PMC7184681.
Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2032-2045. doi: 10.2215/CJN.11491116. Epub 2017 May 18. PMID: 28522654; PMCID: PMC5718284.
Reidy K, Kang HM, Hostetter T, Susztak K. Molecular mechanisms of diabetic kidney disease. J Clin Invest. 2014 Jun;124(6):2333-40. doi: 10.1172/JCI72271. Epub 2014 Jun 2. PMID: 24892707; PMCID: PMC4089448.
Sakai N, Wada T. Revisiting inflammation in diabetic nephropathy: the role of the Nlrp3 inflammasome in glomerular resident cells. Kidney Int. 2015 Jan;87(1):12-4. doi: 10.1038/ki.2014.322. PMID: 25549120.
Guiteras R, Flaquer M, Cruzado JM. Macrophage in chronic kidney disease. Clin Kidney J. 2016 Dec;9(6):765-771. doi: 10.1093/ckj/sfw096. Epub 2016 Oct 5. PMID: 27994852; PMCID: PMC5162417.
Lampropoulou IT, Stangou M, Papagianni A, Didangelos T, Iliadis F, Efstratiadis G. TNF-α and microalbuminuria in patients with type 2 diabetes mellitus. J Diabetes Res. 2014;2014:394206. doi: 10.1155/2014/394206. Epub 2014 Dec 22. PMID: 25587544; PMCID: PMC4284977.
Alicic RZ, Johnson EJ, Tuttle KR. Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Adv Chronic Kidney Dis. 2018 Mar;25(2):181-191. doi: 10.1053/j.ackd.2017.12.002. PMID: 29580582.
Pichler R, Afkarian M, Dieter BP, Tuttle KR. Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. Am J Physiol Renal Physiol. 2017 Apr 1;312(4):F716-F731. doi: 10.1152/ajprenal.00314.2016. Epub 2016 Aug 24. PMID: 27558558; PMCID: PMC6109808.
Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes. 2019 Feb;68(2):248-257. doi: 10.2337/dbi18-0007. Erratum in: Diabetes. 2019 May;68(5):1094. doi: 10.2337/db19-er05a. PMID: 30665953.
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28. PMID: 27470878.
American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S175-S184. doi: 10.2337/dc22-S011. Erratum in: Diabetes Care. 2022 Mar 1;45(3):758. doi: 10.2337/dc22-er03. Erratum in: Diabetes Care. 2022 Sep 01;45(9):2182-2184. doi: 10.2337/dc22-ad08a. PMID: 34964873.
Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, Lo KB, Tuttle K, Vaduganathan M, Ventura H, McCullough PA; American Heart Association Council on the Kidney in Cardiovascular Disease; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Lifestyle and Cardiometabolic Health. Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation. 2020 Oct 27;142(17):e265-e286. doi: 10.1161/CIR.0000000000000920. Epub 2020 Sep 28. Erratum in: Circulation. 2020 Oct 27;142(17):e304. doi: 10.1161/CIR.0000000000000935. Erratum in: Circulation. 2021 Jun;143(22):e1019-e1020. doi: 10.1161/CIR.0000000000000982. PMID: 32981345.
Singh AP, Kalil RS, Weir MR. Role of Sodium-Glucose Cotransporter 2 Inhibitors for Management of Diabetes Mellitus in Renal Transplant Recipients and Management Strategies for Posttransplant Hypertension. Am J Nephrol. 2023;54(3-4):136-144. doi: 10.1159/000530296. Epub 2023 Mar 24. PMID: 36966528.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14. PMID: 30990260.
Fathi A, Vickneson K, Singh JS. SGLT2-inhibitors; more than just glycosuria and diuresis. Heart Fail Rev. 2021 May;26(3):623-642. doi: 10.1007/s10741-020-10038-w. Epub 2020 Dec 4. PMID: 33274396; PMCID: PMC8024235.
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S55-S64. doi: 10.2337/dc18-S006. PMID: 29222377.
International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009 Jul;32(7):1327-34. doi: 10.2337/dc09-9033. Epub 2009 Jun 5. PMID: 19502545; PMCID: PMC2699715.
Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019 Jul;62(7):1154-1166. doi: 10.1007/s00125-019-4859-4. Epub 2019 Apr 17. PMID: 31001673; PMCID: PMC6560022.
Sen T, Li J, Neuen BL, Neal B, Arnott C, Parikh CR, Coca SG, Perkovic V, Mahaffey KW, Yavin Y, Rosenthal N, Hansen MK, Heerspink HJL. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia. 2021 Oct;64(10):2147-2158. doi: 10.1007/s00125-021-05512-5. Epub 2021 Aug 20. PMID: 34415356; PMCID: PMC8423682.
Dekkers CCJ, Petrykiv S, Laverman GD, Cherney DZ, Gansevoort RT, Heerspink HJL. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018 Aug;20(8):1988-1993. doi: 10.1111/dom.13301. Epub 2018 Apr 23. PMID: 29573529; PMCID: PMC6055757.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID: 32970396.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. PMID: 26378978.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12. PMID: 28605608.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS; DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019 Jan 24;380(4):347-357. doi: 10.1056/NEJMoa1812389. Epub 2018 Nov 10. PMID: 30415602.
Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs Context. 2020 Feb 28;9:2019-11-3. doi: 10.7573/dic.2019-11-3. PMID: 32165892; PMCID: PMC7051244.
Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Barsotti E, Clerico A, Muscelli E. Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care. 2017 Jun;40(6):771-776. doi: 10.2337/dc16-2724. Epub 2017 Mar 21. PMID: 28325783.
Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S, Han X, Ji L. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2018 Jan;26(1):70-80. doi: 10.1002/oby.22066. Epub 2017 Nov 22. PMID: 29165885.
Danpanichkul P, Manosroi W, Nilsirisuk T, Tosukhowong T. Predictors of weight reduction effectiveness of SGLT2 inhibitors in diabetes mellitus type 2 patients. Front Endocrinol (Lausanne). 2024 Jan 24;14:1251798. doi: 10.3389/fendo.2023.1251798. PMID: 38327904; PMCID: PMC10849059.
Apovian CM, Okemah J, O'Neil PM. Body Weight Considerations in the Management of Type 2 Diabetes. Adv Ther. 2019 Jan;36(1):44-58. doi: 10.1007/s12325-018-0824-8. Epub 2018 Nov 21. PMID: 30465123; PMCID: PMC6318231.
Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 Aug 20;159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007. PMID: 24026259.
Yamazaki T, Mimura I, Tanaka T, Nangaku M. Treatment of Diabetic Kidney Disease: Current and Future. Diabetes Metab J. 2021 Jan;45(1):11-26. doi: 10.4093/dmj.2020.0217. Epub 2021 Jan 22. PMID: 33508907; PMCID: PMC7850867.
Liu Y, Wang S, Jin G, Gao K, Wang S, Zhang X, Zhou K, Cai Y, Zhou X, Zhao Z. Network pharmacology-based study on the mechanism of ShenKang injection in diabetic kidney disease through Keap1/Nrf2/Ho-1 signaling pathway. Phytomedicine. 2023 Sep;118:154915. doi: 10.1016/j.phymed.2023.154915. Epub 2023 Jun 10. PMID: 37392674.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Michał Szczepański, Marcin Kuliga, Mateusz Bajak, Julia Słowik, Julia Inglot, Jadwiga Inglot, Dominik Maciej Feret, Daniel Zapasek, Maciej Mamczur, Damian Sowa
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 42
Number of citations: 0
